CORT Q3 2024 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$183M+47.7% YoY

Gross Profit

$180M98.4% margin

Operating Income

$47M25.5% margin

Net Income

$47M25.6% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+11.4%

Cash Flow

Operating Cash Flow

$74M

Free Cash Flow

$72M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$784M

Total Liabilities

$145M

Stockholders' Equity

$639M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$183M	$124M	+47.7%
Gross Profit	$180M	$122M	+47.3%
Operating Income	$47M	$31M	+49.5%
Net Income	$47M	$31M	+48.8%